Профиль China Biologic Products Holdings Inc Registered Shs
China Biologic Products Holdings, Inc. (NASDAQ: CBPO), is a leading fully integrated plasma-based biopharmaceutical company in China. Their core capabilities include plasma collection, research and development, manufacturing, and commercialization of human plasma-based biopharmaceutical products. Their company was founded in 2002 and was listed on NASDAQ in 2009. Their products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. Backed by robust research and development capabilities, they aim to capture substantially all of the value along the plasma products value chain, and to develop their technology to enhance life quality and create value for more patients. They have expanded their product portfolio to eight categories of plasma-based products, including human albumin, immunoglobulin for intravenous injection and coagulation factor products, as well as other biopharmaceutical products, and they continue to make progress on new pipeline products.